Influenza Approved Articles & Analysis
2 news found
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that it has successfully developed an ImplaVax®-enabled, solid-dose recombinant H7N9 pandemic influenza vaccine and delivered proof-of-concept ...
This work leverages Micron’s technology, which has already been successfully evaluated in clinical studies including a Phase 1 trial of an FDA-approved seasonal influenza vaccine. Micron’s applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income ...